VIVITRA (Trastuzumab) is used in the treatment of breast cancer and stomach cancer. It is a humanized monoclonal anti-HER2 (Human epidermal growth factor receptor 2) antibody. It triggers body’s immune system – NK (Natural Killer) cells to destroy cancer cells. VIVITRA is prescription drug.
Manufacturer : Zydus Cadila Healthcare Limited
Strengths available : 150mg & 440mg
Storage : Store at temperature between 2°C – 8°C
Warnings : Unsafe to use during pregnancy
Vivitra should be administered as intravenous infusion.
Do not administer as an intravenous push or bolus.
Weekly Schedule: The recommended initial loading dose is 4 mg/kg body weight Vivitra administered as a 90-minute intravenous infusion. Patients should be observed for fever and chills or other infusion-associated symptoms. Interruption of the infusion may help control such symptoms. The infusion may be resumed when symptoms abate.
Subsequent Doses: The recommended weekly dose of Vivitra is 2 mg/kg body weight. If the prior dose was well tolerated, the dose can be administered as a 30-minute infusion.
Patients should be observed for fever and chills or other infusion-associated symptoms.
Side effects : Common side effects are Nausea, Headache, Rash, Reduced blood platelets, Congestive cardiac failure, Insomnia (difficulty in sleeping), Infection, Upper respiratory tract infection, Nasopharyngitis, Fatigue, Fever, Anemia, Chills, Diarrhoea, Cough, Weight loss, Altered taste, Mucosal inflammation, Decreased white blood cell count (neutrophils), Stomatitis (Inflammation of the mouth).